GlycoSeLect
GlycoSeLect specializes in the development and production of glycoprotein separation technology using lectin chemistry.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
€450k | Seed | ||
| Total Funding | 000k | ||
| EUR | 2015 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| % profit margin | (74 %) |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), innovative technology for the analysis and purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in:
• Basic R&D – Glycobiology & Glycoproteomics.
• Biomarker Discover & Biomedical Diagnostics.
• The Biopharmaceutical Industry.
• Vaccines
• Cosmetics
GlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including:
• Simplified, rapid & cost effective production through recombinant expression in Escherichia coli.
• High purity & consistent performance.
• Genetically enhanced glycan binding properties (specificity & affinity).
• Scalable production facilitating utilization for large scale applications.
For more information please visit our website at www.glycoselect.com